NCT06060405
Durvalumab and Oleclumab in Resectable PDAC
Recruiting · Phase 2 · University Health Network, Toronto · registry updated 2026-06-23
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
This is a multi-site Canadian, window of opportunity study to evaluate the immune activity of durvalumab and oleclumab in resectable pancreatic ductal adenocarcinoma (PDAC) when given prior to surgery.
Inclusion
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Weight ≥ 35 kg
- Have a life expectancy ≥ 12 weeks
- Have histologically or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC).
- Upfront resectable PDAC
- Have adequate organ and marrow function required for the study
Exclusion
- Receipt of any conventional or investigational anticancer therapy within 21 days or palliative radiotherapy within 14 days prior to the scheduled first dose of study treatment
- Prior receipt of any immune-mediated therapy including, but not limited to, other anti CTLA-4, anti-PD-1, anti-PD-L1 including durvalumab antibodies and agents targeting CD73, CD39, or adenosine receptors, excluding therapeutic anticancer vaccines.
- Concurrent enrolment in another therapeutic clinical study. Enrolment in observational studies will be allowed.
- Have a history of Grade 3 or greater thromboembolic events in the prior 3 months or thromboembolic event of any grade with ongoing symptoms.
- Have prior history of myocardial infarction, transient ischemic attack, congestive heart failure ≥ Class 3 based on New York Heart Association Functional Classification or stroke within the past 3 months prior to the scheduled first dose of study treatment.
- Active or prior documented autoimmune disorders within the past 3 years prior to the scheduled first dose of study treatment with the following exceptions